Xspray Pharma appoints Global Head of Marketing and Sales

Regulatory press release 2022-02-07

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) announced today that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022.

“At the beginning of the year, Xspray Pharma reached a substantial milestone when the FDA accepted to review our first product. This means that we are getting closer to the commercialization phase. Anna-Karin’s solid experience in hematology, in combination with a broad understanding of the international industry – especially in the US – means we can now begin building up the commercial aspect of the organization. I am very much looking forward to welcoming her to the company,” says Per Andersson, CEO of Xspray Pharma.

With lengthy Swedish and international experience in drug marketing and sales, Anna-Karin comes most recently from her position as Global Marketing Director at Oncopeptides AB. She previously had similar strategic and operational roles at companies including Novartis, Schering AG and HRA Pharma. Anna-Karin’s background includes both studies in marketing at IHM Business School and studies in nursing at Uppsala University.

“I am impressed with Xspray Pharma’s achievements so far, and I hope to be able to contribute through my international experiences and many years in relevant areas of disease, as well as knowledge that covers both biotech and drugs,” says Anna-Karin Ekberg.

Anna-Karin will take office on March 15, 2022 and will become part of Xspray Pharma’s management group.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021. The company’s leading product candidates, Dasynoc (former HyNap-Dasa), HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com